Ab­b­Vie says Rin­voq shines again as main­te­nance ther­a­py for ul­cer­a­tive col­i­tis — but safe­ty con­cerns still loom over JAK class

Even as Rin­voq gets swept up in the FDA’s look in­to the safe­ty of JAK in­hibitors as a class, Ab­b­Vie is con­tin­u­ing to roll out da­ta that it says point to new ap­provals down the road.

The drug has hit the pri­ma­ry and all sec­ondary end­points in a one-year study de­signed to test whether it works as a main­te­nance treat­ment for mod­er­ate to se­vere cas­es of ul­cer­a­tive col­i­tis, Ab­b­Vie said. On the key met­rics of safe­ty, the drug­mak­er re­port­ed no new con­cerns.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER